{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-25-000069","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.936606+00:00","generated_at":"2026-05-21T23:15:36.508132+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"ImmunityBio Reports Q1 2025 Net Product Revenue of $16.5M, Up 129% from Q4 2024","bullets":["Net product revenue for Q1 2025 reached $16.5 million, a 129% increase over $7.2 million in Q4 2024.","ANKTIVA unit sales volume grew 150% in Q1 2025 compared to Q4 2024, with March volume up 69% over February.","Nearly 200 urology practices are registering for ImmunityBio's recombinant BCG Expanded Access Program (EAP).","Positive long-term results from the QUILT 3.032 study showed highest cystectomy avoidance in NMIBC space.","ImmunityBio completed a $75 million equity financing in April 2025 to support operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-25-000069","json":"https://secwatch.observer/filing/0001326110-25-000069.json","markdown":"https://secwatch.observer/filing/0001326110-25-000069.md","text":"https://secwatch.observer/filing/0001326110-25-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/0001326110-25-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000069/ibrx-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-21T23:15:36.508132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}